Table 2.
Treatment characteristics on recurrence with 1st, 2nd, and 3rd line chemotherapy for recurrent or metastatic disease.
| Treatment on 1st recurrence | |
| Surgery alone | 13 (16.7%) |
| Surgery + radiation | 8 (10.3%) |
| Radiation alone | 1 (1.3%) |
| Surgery + chemotherapy | 19 (24.3%) |
| Chemotherapy alone | 18 (23.1%) |
| Surgery + chemotherapy + radiation | 5 (6.4%) |
| Chemotherapy + radiation | 1 (1.3%) |
| Hormonal therapy alone | 3 (3.8%) |
| None | 1 (1.3%) |
| Unknown | 9 (11.6%) |
| Treatment on 2nd recurrence | |
| Surgery alone | 11 (14.1%) |
| Surgery + radiation | 2 (2.6%) |
| Surgery + chemotherapy | 6 (7.7%) |
| Chemotherapy alone | 11 (14.1%) |
| Chemotherapy + radiation | 2 (2.6%) |
| Unknown | 17 (21.8%) |
| Did not obtain NED after 1st recurrence | 29 (37.2%) |
| 1st line chemotherapy additional treatments | |
| Chemotherapy alone | 30 (50.9%) |
| Chemotherapy + surgery | 20 (33.9%) |
| Chemotherapy + radiation | 2 (3.4%) |
| Chemotherapy + radiation + surgery | 4 (6.8%) |
| Chemotherapy + hormonal therapy | 1 (1.7%) |
| Chemotherapy + surgery + hormonal therapy | 2 (3.4%) |
| Chemotherapy given for residual disease after initial treatment | 3 (5.1%) |
| Chemotherapy given for 1st recurrence | 40 (67.8%) |
| Chemotherapy given for 2nd recurrence | 10 (16.9%) |
| Chemotherapy given for 3rd recurrence | 2 (3.4%) |
| Chemotherapy given for 4th recurrence | 2 (3.4%) |
| Chemotherapy given for >4th recurrence | 1 (1.7%) |
| Recurrence chemotherapy given for unknown | 1 (1.7%) |
| 1st line chemotherapy regimens | |
| Doxorubicin based | 28 (47.5%) |
| Doxorubicin alone+ | 4 |
| AI (doxorubicin/ifosfamide) | 9 |
| VAI (vincristine/doxorubicin/ifosfamide) | 1 |
| ADIC (doxorubicin/dacarbazine) | 3 |
| MAID (doxorubicin/ifosfamide/dacarbazine) | 1 |
| Other doxorubicin based∗ | 10 |
| Gemcitabine/docetaxel | 14 (23.7%) |
| Platinum based∗∗ | 12 (20.3%) |
| Other (ifosfamide/paclitaxel (2), paclitaxel, gemcitabine) | 4 (6.8%) |
| Unknown | 1 (1.7%) |
| 2nd line chemotherapy regimens | |
| Doxorubicin based | 6 (25.0%) |
| Doxorubicin alone+ | 3 |
| AI (doxorubicin/ifosfamide) | 3 |
| Gemcitabine/docetaxel | 9 (37.5%) |
| Platinum based (cisplatin/ifosfamide in one patient)∗∗∗ | 4 (16.7%) |
| Other (ifosfamide, paclitaxel, paclitaxel/bevacizumab, irinotecan/dacarbazine, trabectedin) | 5 (20.8%) |
| 3rd line chemotherapy regimens | |
| Doxorubicin based | 4 (36.4%) |
| Doxorubicin alone | 2 |
| AI (doxorubicin/ifosfamide) | 1 |
| ADIC (doxorubicin/dacarbazine) | 1 |
| Platinum based∗∗∗∗ | 2 (18.2%) |
| Other (ifosfamide (2), paclitaxel, I/E++, TMZ+++) | 5 (45.5%) |
Chemotherapy dosing: gemcitabine 675 to 900 mg/m2, docetaxel 75 to 100 mg/m2, vincristine 2 mg, doxorubicin 60 to 75 mg/m2, ifosfamide 7.5 to 10 gm/m2, and dacarbazine 750 to 1000 mg/m2; ∗doxorubicin/cyclophosphamide/cisplatin (1), low-dose doxorubicin/ifosfamide (50 mg/m2, 2.4 gm/m2) (1), doxorubicin/cisplatin (1), vincristine/doxorubicin/cyclophosphamide (1), doxorubicin/cisplatin/paclitaxel (1), doxorubicin/dacarbazine/cyclophosphamide (3), doxorubicin/carboplatin (1), and vincristine/doxorubicin/cyclophosphamide/dacarbazine (1); ∗∗carboplatin/docetaxel (2), bleomycin/etoposide/cisplatin (2), carboplatin/paclitaxel (4), cisplatin with weekly radiation (2), carboplatin/paclitaxel/bevacizumab (1), and carboplatin/cyclophosphamide (1); ∗∗∗carboplatin/docetaxel (1), carboplatin/paclitaxel (1), cisplatin/ifosfamide (1), and carboplatin/gemcitabine (1); ∗∗∗∗carboplatin/gemcitabine (1) and cisplatin/gemcitabine (1); +one patient had liposomal doxorubicin; ++ifosfamide/etoposide; +++temozolomide.